PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 20, 2019Diabetes Care170 citationsOpen Access

Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function—Even Without Albuminuria

View Full Paper
DVDorte VistisenGAGregers S. AndersenÁHÁdám Hulmán

Key Points

Key points are not available for this paper at this time.

Abstract

OBJECTIVE: Persons with diabetes but no chronic kidney disease (CKD) and without albuminuria have the same age-related decline in kidney function as the background population. Whether this also applies following moderate loss in kidney function is unknown. We quantified the impact of albuminuria status on the development of estimated glomerular filtration rate (eGFR) trajectories following CKD stage 3 (CKD3) and assessed potential heterogeneous development patterns among the subgroup with normoalbuminuria. RESEARCH DESIGN AND METHODS: We used repeated clinical measures during up to 16 years of follow-up in 935 persons with type 1 diabetes and 1,984 with type 2 diabetes. Trajectories of eGFR by diabetes type and albuminuria status following CKD3 were estimated with spline mixed-effects models with adjustment for relevant confounders. Latent class trajectory modeling was used to find distinct patterns of eGFR development in the subgroups with normoalbuminuria. RESULTS: in type 1 diabetes and 1.9, 2.1, and 3.0 in type 2 diabetes, respectively. For normoalbuminuria, two distinct eGFR patterns were found, one with accelerated declining eGFR levels. This specific progression pattern was associated with less use of lipid-lowering treatment, renin-angiotensin system blockers, and other antihypertensive treatment. CONCLUSIONS: Our results support a diabetes-dependent decline in kidney function without albuminuria following CKD3, with a subgroup showing a progressive decline. Furthermore, this group seems to be undertreated in terms of cardioprotective and renal protective treatment and suggests that increased attention should be drawn to normoalbuminuric diabetic kidney disease.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Vistisen et al. (2019) studied this question.

synapsesocial.com/papers/6a1c382b4ebd09f3dfa996e5https://doi.org/10.2337/dc19-0349
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Goodpasture syndrome during the course of a Schönlein-Henoch purpura2002 · 1,474 citations
  2. 2Does stage-3 chronic kidney disease matter?: A systematic literature review2010 · 32 citations
  3. 3K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification2002 · 11,661 citations
  4. 4A nonlinear latent class model for joint analysis of multivariate longitudinal data and a binary outcome2006 · 96 citations
  5. 5Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes2001 · 6,040 citations